Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute (SCRI), shared a post by Miami Cancer Institute Research on X, adding:
“Such a delight to deliver the keynote on ‘Re-imagining the Precision Oncology Paradigm’ discussing the paper published in AACR, Cancer Discovery.
Fantastic Friday morning with an amazing panel discussion session and terrific colleagues.”
Quoting Miami Cancer Institute Research’s post:
“Miami Cancer Institute Precision Oncology Symposium kicks off with opening remarks from Manmeet Ahluwalia, and keynote presentations from Luis Diaz and Vivek Subbiah.
highlighting new therapies.”
Title: Rethinking Cancer Drug Development through Tumor-agnostic Precision Medicine
Author: Vivek Subbiah
Read the Full Article in Cancer Discovery.
More posts featuring Vivek Subbiah.
